Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ceforanide

Ceforanide: A Comprehensive Review of Its Use in Clinical Practice

Introduction

Ceforanide is a second-generation cephalosporin antibiotic that has earned its place in the treatment of various bacterial infections due to its broad-spectrum activity against Gram-positive and Gram-negative organisms. It is primarily used in hospital settings for the treatment of serious infections, often as part of empiric therapy or when susceptibility testing has identified the offending pathogen.

Pharmacological Overview

  • Drug Class: Second-generation cephalosporin

  • Chemical Formula: C18H18N6O5S3

  • Molecular Weight: 502.57 g/mol

  • Brand Names: Ceforanide is marketed under various brand names, including Ceforan and Ceforab.

Ceforanide is typically administered parenterally (via intravenous or intramuscular injection) and is widely used in hospitals to treat infections caused by aerobic and anaerobic organisms.

Mechanism of Action

Like all cephalosporins, Ceforanide functions as a beta-lactam antibiotic, inhibiting bacterial cell wall synthesis. It binds to specific proteins known as penicillin-binding proteins (PBPs) that are essential for cell wall formation. By binding to these PBPs, Ceforanide prevents the final stages of peptidoglycan synthesis, which results in the weakening of the bacterial cell wall and ultimately leads to cell lysis.

Ceforanide is bactericidal and demonstrates time-dependent killing, meaning that its effectiveness is closely linked to the duration of exposure to the drug, rather than the peak plasma concentration.

Antibacterial Spectrum

Ceforanide has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, though its activity is not as extensive against Pseudomonas aeruginosa or Enterococcus spp. as some other antibiotics.

Gram-Positive Organisms

  • Staphylococcus aureus (methicillin-sensitive strains)

  • Streptococcus pneumoniae

  • Streptococcus pyogenes

  • Streptococcus viridans group

  • Listeria monocytogenes

Gram-Negative Organisms

  • Escherichia coli

  • Klebsiella pneumoniae

  • Proteus mirabilis

  • Haemophilus influenzae

  • Neisseria gonorrhoeae

  • Moraxella catarrhalis

  • Enterobacter spp.

Anaerobic Bacteria

  • Bacteroides fragilis

  • Clostridium spp. (some strains)

While Ceforanide’s Gram-negative coverage is commendable, it is less effective against Pseudomonas aeruginosa and Acinetobacter spp. compared to other cephalosporins or beta-lactam combinations.

Pharmacokinetics

Ceforanide is typically administered intravenously or intramuscularly, as it is poorly absorbed from the gastrointestinal tract. Its pharmacokinetics are characterized by rapid distribution, relatively high plasma protein binding, and excretion primarily via the kidneys.

Key Pharmacokinetic Properties:

  • Absorption: Given parenterally (IV/IM), Ceforanide bypasses the GI tract and is immediately available for therapeutic action.

  • Plasma Protein Binding: Approximately 85-90% of Ceforanide binds to plasma proteins, which may affect its distribution.

  • Half-Life: Approximately 1.5 to 2 hours in healthy individuals; prolonged in cases of renal impairment.

  • Excretion: Primarily renal, with up to 70% of the drug excreted unchanged in the urine.

The relatively short half-life necessitates frequent dosing, typically every 8 to 12 hours, to maintain therapeutic levels.

Clinical Indications

Ceforanide is mainly used for serious bacterial infections, often in hospitalized patients. It is particularly useful in infections caused by susceptible Gram-positive and Gram-negative organisms. Its broad spectrum makes it a good choice for empirical therapy, especially when the causative agent is unknown.

1. Respiratory Tract Infections

  • Pneumonia (community-acquired and hospital-acquired)

  • Bronchitis and bronchopneumonia

  • Sinusitis

  • Pharyngitis and tonsillitis

2. Urinary Tract Infections (UTIs)

  • Cystitis (bladder infection)

  • Pyelonephritis (kidney infection)

3. Skin and Soft Tissue Infections

  • Cellulitis

  • Wound infections

  • Abscesses (especially in post-surgical patients)

4. Bone and Joint Infections

  • Osteomyelitis

  • Septic arthritis

5. Intra-abdominal Infections

  • Peritonitis

  • Cholecystitis

  • Biliary tract infections

6. Septicemia and Bacteremia

  • Empiric therapy for febrile neutropenic patients

  • Bloodstream infections in immunocompromised individuals

Dosage and Administration

The dosing of Ceforanide depends on the severity of the infection, the patient's age, and their renal function. For adults, the usual recommended dosage is:

  • Mild to moderate infections: 500 mg to 1 g IV every 12 hours

  • Severe infections: 1–2 g IV every 8 hours

Pediatric Dose:

  • Neonates and infants: 20–40 mg/kg/day in divided doses every 12–24 hours

  • Children: 25–50 mg/kg/day in divided doses every 12 hours

The dosage should be adjusted based on renal function to avoid toxicity, particularly in patients with impaired renal clearance.

Adverse Effects

Ceforanide is generally well tolerated, but, like all antibiotics, it can cause side effects. Common adverse effects include:

Gastrointestinal (GI)

  • Nausea

  • Vomiting

  • Diarrhea

  • Abdominal pain

Hematologic

  • Leukopenia (decrease in white blood cell count)

  • Thrombocytopenia (decrease in platelet count)

Renal

  • Elevated serum creatinine (in cases of renal impairment)

  • Acute kidney injury (rare, especially in those with pre-existing renal disease)

Hepatic

  • Elevated liver enzymes (ALT, AST)

  • Hepatitis (rare)

Allergic Reactions

  • Rash

  • Urticaria (hives)

  • Anaphylaxis (rare but serious)

Injection Site Reactions

  • Pain, swelling, or irritation at the injection site

Drug Interactions

As a beta-lactam antibiotic, Ceforanide has several potential drug interactions:

  • Probenecid: Decreases renal excretion of Ceforanide, leading to higher plasma levels and prolonged half-life.

  • Aminoglycosides: Increased risk of nephrotoxicity when used together, so caution is advised.

  • Oral anticoagulants: Ceforanide may enhance the anticoagulant effect, leading to an increased risk of bleeding.

  • Alcohol: Disulfiram-like reactions (flushing, nausea, vomiting) may occur if alcohol is consumed during Ceforanide therapy, though this is less common with second-generation cephalosporins.

Resistance Mechanisms

Ceforanide, like all antibiotics, faces challenges with bacterial resistance. Some key mechanisms of resistance to Ceforanide include:

  • Beta-lactamase production: Some bacteria produce beta-lactamases, enzymes that can break down the beta-lactam ring in Ceforanide, rendering it ineffective. This is especially true for Extended Spectrum Beta-Lactamases (ESBLs) and AmpC producers.

  • Altered penicillin-binding proteins (PBPs): Some organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and enterococci, have altered PBPs that reduce the binding affinity of Ceforanide.

  • Efflux pumps: Some Gram-negative bacteria utilize efflux pumps to expel the antibiotic before it can reach its target.

Strategies to Combat Resistance:

  • Combination therapy: Using Ceforanide in combination with beta-lactamase inhibitors (though this is more common with other cephalosporins).

  • Stewardship programs: Limiting the use of Ceforanide to avoid unnecessary exposure and reduce resistance development.

Clinical Considerations

Special Populations

  • Pregnancy: Ceforanide is classified as Category B by the FDA, indicating that it is generally safe for use in pregnancy, but it should be prescribed only when clearly needed.

  • Lactation: Ceforanide is excreted in breast milk in low concentrations. It is considered safe for use during breastfeeding, but caution is advised.

  • Renal Impairment: Dosage adjustments are needed in patients with impaired renal function to avoid accumulation of the drug and toxicity.

  • Pediatric Use: Ceforanide is safe for use in children, though careful dosing is required, particularly in neonates.

Conclusion

Ceforanide is a potent second-generation cephalosporin that is useful in treating a wide variety of bacterial infections. With its broad spectrum of activity, it remains an important antibiotic for hospital-acquired infections, particularly when broad-spectrum Gram-positive and Gram-negative coverage is required. However, as with all antibiotics, its use must be carefully managed to avoid the development of resistance, and it is generally reserved for serious infections where its benefits outweigh the risks. The evolution of bacterial resistance and the rise of multi-drug resistant organisms underscore the importance of antimicrobial stewardship and appropriate antibiotic selection.